Boston Scientific Corporation (BSX) has demonstrated a robust performance in the third quarter of 2023, underpinned by significant growth across its various segments. The company reported net sales of $3.527 billion, marking an 11.2% increase compared to the same period last year. This growth is even more pronounced on an operational and organic basis, with figures of 11.1% and 10.2%, respectively.
BSX Reports $0.50 EPS and $3.73B in Revenue for Fiscal Q3
Earnings per share (EPS) also showed a positive trend, with a reported EPS of $0.34, significantly higher than the $0.12 in Q3 2022. Adjusted EPS was $0.50, compared to $0.43 in the prior year, reflecting the company’s effective management and strategic initiatives.
Boston Scientific’s performance this quarter has exceeded the market expectations set for them. Analysts had anticipated an EPS of $0.51 and revenue of $3.6 billion. However, the company reported an adjusted EPS of $0.50 and revenue of $3.73 billion. While slightly below the expected EPS, the company’s revenue aligns closely with forecasts.
Guidance
Boston Scientific has issued optimistic guidance for the fourth quarter of 2023, setting high expectations for continued growth. The company forecasts reported net sales growth between 9% and 11% and an adjusted EPS range of $0.49 to $0.52.
These projections indicate confidence in sustained momentum and operational efficiency. For the full year of 2023, the guidance includes an expected reported net sales growth of around 11% and an adjusted EPS of $1.99 to $2.02. This forward-looking outlook underscores the company’s strategic initiatives and its commitment to delivering value to its stakeholders.
Disclaimer: The author does not hold or have a position in any securities discussed in the article.
The post Boston Scientific Corporation (BSX) Reports $0.50 Adjusted EPS, $3.73B Revenue for Q3 appeared first on Tokenist.
